• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

免疫检查点抑制剂在完全切除的非小细胞肺癌患者中作为辅助治疗。

Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.

作者信息

Pirker Robert

机构信息

Department of Medicine I, Medical University of Vienna, Vienna, Austria.

出版信息

Curr Opin Oncol. 2024 Jan 1;36(1):24-28. doi: 10.1097/CCO.0000000000001003. Epub 2023 Oct 20.

DOI:10.1097/CCO.0000000000001003
PMID:37865822
Abstract

PURPOSE OF REVIEW

The purpose of the review is to summarize the current status of immune checkpoint inhibitors as adjuvant therapy in patients with resected nonsmall cell lung cancer (NSCLC).

RECENT FINDINGS

The IMpower010 phase 3 trial demonstrated improved disease-free survival and, in case of PD-L1 at least 50%, also improved overall survival for atezolizumab compared to best supportive care among patients with completely resected stage II-IIIA NSCLC. The PEARLS/KEYNOTE-091 trial showed increased disease-free survival for pembrolizumab among patients with stage IB-IIIA NSCLC. Trials with nivolumab and durvalumab are ongoing.

SUMMARY

Atezolizumab or pembrolizumab have become options for adjuvant therapy in patients with completely resected NSCLC.

摘要

综述目的

本综述旨在总结免疫检查点抑制剂作为已切除非小细胞肺癌（NSCLC）患者辅助治疗的现状。

最新研究结果

IMpower010 3期试验表明，对于完全切除的II-IIIA期NSCLC患者，与最佳支持治疗相比，阿替利珠单抗可改善无病生存期，且在PD-L1至少为50%的情况下，还可改善总生存期。PEARLS/KEYNOTE-091试验显示，帕博利珠单抗可提高IB-IIIA期NSCLC患者的无病生存期。纳武利尤单抗和度伐利尤单抗的试验正在进行中。

总结

阿替利珠单抗或帕博利珠单抗已成为完全切除的NSCLC患者辅助治疗的选择。

相似文献

1
Immune checkpoint inhibitors as adjuvant therapy in patients with completely resected nonsmall cell lung cancer.免疫检查点抑制剂在完全切除的非小细胞肺癌患者中作为辅助治疗。
Curr Opin Oncol. 2024 Jan 1;36(1):24-28. doi: 10.1097/CCO.0000000000001003. Epub 2023 Oct 20.
2
Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.辅助阿特珠单抗治疗辅助化疗后切除的 IB-IIIA 期非小细胞肺癌（IMpower010）：一项随机、多中心、开放标签、III 期临床试验。
Lancet. 2021 Oct 9;398(10308):1344-1357. doi: 10.1016/S0140-6736(21)02098-5. Epub 2021 Sep 20.
3
Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial.帕博利珠单抗对比安慰剂作为完全切除的 IB 期-IIIA 期非小细胞肺癌的辅助治疗（PEARLS/KEYNOTE-091）：一项随机、三盲、III 期试验的中期分析。
Lancet Oncol. 2022 Oct;23(10):1274-1286. doi: 10.1016/S1470-2045(22)00518-6. Epub 2022 Sep 12.
4
Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010).阿特珠单抗辅助治疗日本可切除的 IB-IIIA 期非小细胞肺癌患者（IMpower010）。
Cancer Sci. 2022 Dec;113(12):4327-4338. doi: 10.1111/cas.15564. Epub 2022 Sep 21.
5
Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase III trial.阿特珠单抗辅助化疗用于可切除 II-IIIA 期非小细胞肺癌的总生存期：一项随机、多中心、开放标签、III 期试验（IMpower010）。
Ann Oncol. 2023 Oct;34(10):907-919. doi: 10.1016/j.annonc.2023.07.001. Epub 2023 Jul 17.
6
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与含或不含贝伐珠单抗的一线含铂化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2020 Dec 14;12(12):CD013257. doi: 10.1002/14651858.CD013257.pub2.
7
Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.比较单药或联合免疫检查点抑制剂与一线含或不含贝伐珠单抗的铂类化疗方案用于晚期非小细胞肺癌患者。
Cochrane Database Syst Rev. 2021 Apr 30;4(4):CD013257. doi: 10.1002/14651858.CD013257.pub3.
8
The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.基于血液的肿瘤突变负担水平与 PD-1/PD-L1 抑制剂在晚期非小细胞肺癌中的疗效关系：系统评价和荟萃分析。
BMC Cancer. 2021 Nov 13;21(1):1220. doi: 10.1186/s12885-021-08924-z.
9
Safety of adjuvant atezolizumab after pneumonectomy/bilobectomy in stage II-IIIA non-small cell lung cancer in the randomized phase III IMpower010 trial.在随机 III 期 IMpower010 试验中，肺切除术/双肺叶切除术治疗 II 期-IIIA 期非小细胞肺癌患者中，辅助阿替利珠单抗的安全性。
J Thorac Cardiovasc Surg. 2023 Sep;166(3):655-666.e7. doi: 10.1016/j.jtcvs.2023.01.012. Epub 2023 Jan 21.
10
Determining the optimal PD-1/PD-L1 inhibitors for the first-line treatment of non-small-cell lung cancer with high-level PD-L1 expression in China.在中国，对于高 PD-L1 表达的非小细胞肺癌患者，确定最佳的 PD-1/PD-L1 抑制剂作为一线治疗药物。
Cancer Med. 2021 Sep;10(18):6344-6353. doi: 10.1002/cam4.4191. Epub 2021 Aug 12.

引用本文的文献

1
The role of PD-L1 in patients with non-small cell lung cancer receiving neoadjuvant immune checkpoint inhibitor plus chemotherapy: a meta-analysis.PD-L1 在接受新辅助免疫检查点抑制剂联合化疗的非小细胞肺癌患者中的作用：一项荟萃分析。
Sci Rep. 2024 Oct 31;14(1):26200. doi: 10.1038/s41598-024-78159-y.